57 groups have lost their patience.
The patient advocacy world is no longer sitting quietly while the White House reshuffles the deck chairs on federal funding. The Office of Management and Budget (OMB) is pushing a new rule. It changes 2 CFR Part 2.00. The draft was released May 29. Now 57 organizations—banding together under “United for Cures”—are screaming into the void of Congress.
They aren’t asking. They are demanding.
The letter went straight to the top: House Speaker Mike Johnson, Senate Minority Leader Hakeem Jeffires, Senate Majority Leader John Thuhne and House Minority Leader Chuck Schumer. The message? Do something.
Why Everyone Is Nervous
Let’s be clear about what’s happening here. If this OMB rule kicks in on October 1 it gives the President—Donald Trump—and his political appointees a leash. A long one.
They can decide where money goes. And who doesn’t get it.
It is an unprecedented power shift. The United for Cures coalition, which includes heavyweights like the American Cancer Society, Susan G. Komen and the American Heart Association, sees grave consequences.
“In all more than 300 changes have been proposed… will have far reaching consequences on US global leadership.”
Three hundred changes. Just like that.
The organizations represent people fighting life or death battles. Think Alzheimer’s. Prostate cancer. Lung disease. When your funding comes down to a political whim your life depends on who wins the election. Not who finds the cure.
Shouldn’t Congress debate this first? They are urging legislators to block it so they can actually understand the mess they are walking into.
The Clock Is Ticking
The public only has 45 days to weigh in. A bit short for rules this massive?
The comment window slams shut on July 13 at 11:59 PM ET. Over 290,001 people have already spoken on Regulations.gov. The concerns are consistent. Terrifyingly so.
Here is what they are saying:
– Research grants could vanish. Overnight. No recourse. Clinical trial patients get pulled off meds. Hope evaporates. Millions of dollars go up in smoke.
– The US loses its scientific crown to countries like China.
– Money flows away from what Congress intended. Political priorities trump medical need.
– Unelected bureaucrats pick the winners. Not scientists. This destabilizes the entire research ecosystem.
It creates a chill. Literally. A “chilling effect” on researchers who might hesitate to pitch multi-year studies if they can’t count on funding past week three. The pipeline for discoveries dries up.
California Draws the Line
The rest of the country? Still watching. California acted.
Senator Adam Schiff, Representative Zoe Lofgren and 42 other CA lawmakers sent a letter on July 8. It went to OMB Director Russell Vought. Their request: Rescind the rule. Immediately.
The letter argues that the rule allows political whims to override public welfare.
“Setting the stage for politically motivated decision making that places the whims of the President OVER the well being of the American people.”
It is not just about medicine. Space exploration. Environmental tech. Higher education. The whole house of cards leans on grant money. The CA lawmakers warn we could backslide globally for generations. Innovation requires stability. This rule brings chaos.
But California isn’t the only place this bites. It hits every state. Every business. Every government agency. And probably the local alpaca sanctuary somewhere. The point is it is everywhere.
The President gets the final say. Congress watches from the sidelines. The deadline approaches. The comments pile up. The question hangs in the air heavy and unanswered.
Will Congress step up?
